eriocalyxin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

eriocalyxin B: isolated from Isodon Eriocalyx; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Flora	Rank	Flora Definition	Family	Family Definition
Isodon	genus	A plant genus of the family LAMIACEAE used in TRADITIONAL CHINESE MEDICINE.[MeSH]	Lamiaceae	The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID Source	ID
PubMed CID	16202215
CHEMBL ID	2088267
SCHEMBL ID	22526009
MeSH ID	M0506007

Synonyms (13)

Synonym
eriocalyxin b
CHEMBL2088267
84745-95-9
AKOS032948099
BCP23955
nsc 637462; rabdosianone; rabdosianone i
CS-0019713
HY-N2303
(1s,2s,5r,8s,9s,10s,11r)-9,10-dihydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadec-13-ene-7,15-dione
SCHEMBL22526009
MS-25286
DTXSID801317705
eriocalyxinb

Research Excerpts

Overview

Eriocalyxin B (EriB) is a natural medicine that antagonizes inflammation. It is purified from Isodon eriocalyx var.

Excerpt	Reference	Relevance
"Eriocalyxin B (EriB) is a natural medicine that antagonizes inflammation."	( Eriocalyxin B ameliorated Crohn's disease-like colitis by restricting M1 macrophage polarization through JAK2/STAT1 signalling. Cheng, Y; Geng, Z; Huang, J; Li, J; Li, Q; Li, Y; Song, X; Wang, L; Wang, Y; Wu, X; Xu, M; Yang, Z; Zhang, H; Zhang, J; Zhang, X; Zhao, T; Zuo, L, 2023)	3.07
"Eriocalyxin B (EriB) is a natural diterpenoid purified from Isodon eriocalyx var. "	( Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways. Chen, QS; Chen, SJ; Chen, Z; Jiang, XX; Shen, ZX; Shi, WY; Sun, HD; Wang, L; Zhang, YW; Zhao, WL, 2010)	3.25

Pharmacokinetics

Excerpt	Reference	Relevance
"The purpose of this study was to determine EriB in plasma by using the method of HPLC and collect the preclinical pharmacokinetic parameters of EriB."	( A validated HPLC method for the determination of eriocalyxin B in plasma and its application to pharmacokinetic studies. Chen, HY; Chen, JX; Cui, Z; Sun, JH; Wang, Z; Wu, H; Yuan, Q, 2012)	0.63

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID683414	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	2012	Journal of natural products, Jun-22, Volume: 75, Issue:6	Laxiflorolides A and B, epimeric bishomoditerpene lactones from Isodon eriocalyx.
AID683413	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	2012	Journal of natural products, Jun-22, Volume: 75, Issue:6	Laxiflorolides A and B, epimeric bishomoditerpene lactones from Isodon eriocalyx.
AID683415	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2012	Journal of natural products, Jun-22, Volume: 75, Issue:6	Laxiflorolides A and B, epimeric bishomoditerpene lactones from Isodon eriocalyx.
AID683416	Cytotoxicity against human SW480 cells after 48 hrs by MTT assay	2012	Journal of natural products, Jun-22, Volume: 75, Issue:6	Laxiflorolides A and B, epimeric bishomoditerpene lactones from Isodon eriocalyx.
AID683412	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	2012	Journal of natural products, Jun-22, Volume: 75, Issue:6	Laxiflorolides A and B, epimeric bishomoditerpene lactones from Isodon eriocalyx.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (3.45)	18.2507
2000's	5 (17.24)	29.6817
2010's	18 (62.07)	24.3611
2020's	5 (17.24)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	19.63 (24.57)
Research Supply Index	3.40 (2.92)
Research Growth Index	5.40 (4.65)
Search Engine Demand Index	15.26 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (19.63)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (3.45%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	28 (96.55%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.	2.17	1	methylpyridines; phenylpyridine; tetrahydropyridine	neurotoxin
deoxycytidine [no description available]	2.17	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.07	1	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
1-methyl-4-phenylpyridinium 1-Methyl-4-phenylpyridinium: An active neurotoxic metabolite of 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE. The compound reduces dopamine levels, inhibits the biosynthesis of catecholamines, depletes cardiac norepinephrine and inactivates tyrosine hydroxylase. These and other toxic effects lead to cessation of oxidative phosphorylation, ATP depletion, and cell death. The compound, which is related to PARAQUAT, has also been used as an herbicide.. N-methyl-4-phenylpyridinium : A pyridinium ion that is N-methylpyridinium having a phenyl substituent at the 4-position.	2.17	1	pyridinium ion	apoptosis inducer; herbicide; human xenobiotic metabolite; neurotoxin
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	7.17	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
bruceine d bruceine D: from fructus of Brucea javanica (Chinese name Yadanzi). bruceine D : A quassinoid that is 13,20-epoxypicras-3-ene substituted by hydroxy groups at positions 1, 11, 12, 14 and 15 and oxo groups at positions 2 and 16. Isolated from the ethanol extract of the stem of Brucea mollis, it exhibits cytotoxic activity.	3.19	1
wortmannin [no description available]	2.25	1	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
enmein enmein: structure	2.03	1	delta-lactone	metabolite
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.11	1	cysteinium	fundamental metabolite
oridonin [no description available]	2.03	1
gibberellins [no description available]	2.21	1

Condition	Relationship Strength	Studies
Colorectal Cancer [description not available]	2.31	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.31	1
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.72	2
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.72	2
Colitis, Granulomatous [description not available]	2.6	1
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	7.6	1
Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.	2.6	1
Cancer of Prostate [description not available]	2.44	2
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.44	2
Electron Transport Chain Deficiencies, Mitochondrial [description not available]	2.21	1
Mitochondrial Diseases Diseases caused by abnormal function of the MITOCHONDRIA. They may be caused by mutations, acquired or inherited, in mitochondrial DNA or in nuclear genes that code for mitochondrial components. They may also be the result of acquired mitochondria dysfunction due to adverse effects of drugs, infections, or other environmental causes.	2.21	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.61	2
Acute Bacterial Prostatitis [description not available]	2.25	1
Pelvic Pain Pain in the pelvic region of genital and non-genital origin.	7.25	1
Prostatitis Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.	7.25	1
Breast Cancer [description not available]	7.74	3
Experimental Mammary Neoplasms [description not available]	2.15	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.74	3
Adenocarcinoma, Basal Cell [description not available]	2.52	2
Cancer of Pancreas [description not available]	4.4	7
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	7.52	2
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	4.4	7
Idiopathic Parkinson Disease [description not available]	2.17	1
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	2.17	1
Hepatocellular Carcinoma [description not available]	2.1	1
Cancer of Liver [description not available]	2.1	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.1	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.1	1
Cancer of Colon [description not available]	2.13	1
Angiogenesis, Pathologic [description not available]	2.53	2
Invasiveness, Neoplasm [description not available]	2.13	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.13	1
Germinoblastoma [description not available]	2.05	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	7.05	1
Cancer of Ovary [description not available]	2.06	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.06	1
Allergic Encephalomyelitis [description not available]	2.08	1
Chromosomal Translocation [description not available]	2.03	1
Acute Myelogenous Leukemia [description not available]	2.03	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	2.03	1
Anaplastic Astrocytoma [description not available]	1.98	1
Cancer of Lung [description not available]	1.98	1
Astrocytoma Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)	1.98	1
Lung Neoplasms Tumors or cancer of the LUNG.	1.98	1

chemdatabank.com